

In re application of: Mitchell Shirvan and Meir Bialer

March 31, 2003

Serial No.: 09/932,370

Filed: August 17, 2001



RECEIVED
APR 07 2003
TECH CENTER 1000/2003

For: USE OF DERIVATIVES OF VALPROIC ACID AMIDES AND 2-VALPROENIC ACID AMIDES FOR THE TREATMENT OR PREVENTION OF PAIN AND/OR HEADACHE DISORDERS

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

S I R:

Transmitted herewith is an amendment to the above-identified application.

Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

☒ No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
							SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	92	-	* 96	=	*** 0	x	9.00	18.00	=	0
Independent Claims	5	-	** 8	=	*** 0	x	42.00	84.00	=	0
Multiple Dependent Claims(s) Presented <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No							140.00	280.00		0
For First Time:							TOTAL ADDITIONAL \$ FEE			
							0			

*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

**If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

***If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicants : Mitchel Shirvan and Meir Bialer
U.S. Serial No.: 09/932,370
Filed : August 17, 2001

RECEIVED
APR 07 2003
TECH CENTER 1000/2300

Amendment Transmittal Letter
Page 2

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

_____ Please charge Deposit Account No. _____
in the amount of \$ _____.


_____ A check in the amount of \$ _____ is enclosed.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

☒ Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.


☒ Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 3/31/03
Date
John P. White
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992



Docket No. 62812-A/JPW/GJG/CSN

RECEIVED

APR 07 2003

TECH. CENTER 1600/2200/411/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mitchell Shirvan and Meir Bialer
Serial No.: 09/932,370 Examiner: San-ming Hui
Filed : August 17, 2001 Group Art Unit: 1617
For : USE OF DERIVATIVES OF VALPROIC ACID AMIDES AND 2-
VALPROENIC ACID AMIDES FOR THE TREATMENT OR
PREVENTION OF PAIN AND/OR HEADACHE DISORDERS

1185 Avenue of the Americas
New York, New York 10036
March 31, 2003

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**AMENDMENT IN RESPONSE TO
DECEMBER 31, 2002 OFFICE ACTION**

This Amendment is submitted in response to the December 31, 2002 Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the December 31, 2002 Office Action is due March 31, 2003. Accordingly, this Amendment is being timely filed.

In the claims

Please cancel claims 46, 54, 78 and 92 without prejudice to applicants' rights to pursue the subject matter of these claims in this or a related application.

Additionally, please amend claims 1, 16-21, 26-27, 40-45, 47, 55, 62-67, 72, 73, 86-91, and 93-96 as set forth below. The amendments to the previously pending claims are indicated by underline of added material and bracketing of deleted material in the Version with Markings to Show Changes Made attached hereto as **Exhibit 1**.